{"transactions":[{"id":1440930,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T16:51:04.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80189,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":80189},"source":{"system":"sec-edgar","filing":"0000950170-24-090908","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090908/ownership.xml","form_type":"4"}},{"id":1440929,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T16:51:04.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65679781,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of common stock held directly by BC Perception Holdings, LP (\"BC Perception\"). Christopher Gordon is a Partner of Bain Capital Investors, LLC (\"BCI\"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090908","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090908/ownership.xml","form_type":"4"}},{"id":1440928,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T16:51:04.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10461,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are represented by restricted stock units (\"RSUs\"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares are represented by restricted stock units (\"RSUs\"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090908","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090908/ownership.xml","form_type":"4"}},{"id":1440927,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T16:51:04.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3282,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":10461,"source":{"system":"sec-edgar","filing":"0000950170-24-090908","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090908/ownership.xml","form_type":"4"}},{"id":1486986,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T17:22:35.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10461,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the\nIssuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the\nIssuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company."}],"balance_after":13743,"source":{"system":"sec-edgar","filing":"0000950170-24-070908","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024070908/ownership.xml","form_type":"4"}},{"id":1758184,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-18T16:30:16.000Z","date":"2023-10-16","kind":"purchase","planned":false,"acquired":true,"shares":5480052,"price":22.81,"value":124999986.12,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP (\"BC Perception\"). Christopher Gordon is a Partner of Bain Capital Investors, LLC (\"BCI\"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":65679781,"source":{"system":"sec-edgar","filing":"0000899243-23-019970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323019970/doc4.xml","form_type":"4"}},{"id":1860753,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T17:09:02.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":13780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":13780,"derivative":{"exercise_price":32.6,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":13780},"source":{"system":"sec-edgar","filing":"0000899243-23-015226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323015226/doc4.xml","form_type":"4"}},{"id":1860752,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T17:09:02.000Z","date":"2023-06-07","kind":"other","planned":false,"acquired":false,"shares":432627,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On June 7, 2023, BC Perception Holdings, LP (\"BC Perception\") distributed an aggregate of 432,627 shares of the Issuer's common stock (the \"Distributed Shares\") to certain of its limited partners in a pro-rata in-kind distribution to such limited partners in connection with a redemption of their partnership interests. Mr. Gordon did not have a pecuniary interest in any of the Distributed Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Christopher Gordon is a Partner of Bain Capital Investors, LLC (\"BCI\"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":60199729,"source":{"system":"sec-edgar","filing":"0000899243-23-015226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323015226/doc4.xml","form_type":"4"}},{"id":1860751,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T17:09:02.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":3282,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":3282,"source":{"system":"sec-edgar","filing":"0000899243-23-015226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924323015226/doc4.xml","form_type":"4"}},{"id":2230083,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T17:11:01.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":23459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":23459,"derivative":{"exercise_price":24.35,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":23459},"source":{"system":"sec-edgar","filing":"0000899243-22-022865","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924322022865/doc4.xml","form_type":"4"}},{"id":2670346,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T20:26:41.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":42950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date."}],"balance_after":42950,"derivative":{"exercise_price":13.93,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":42950},"source":{"system":"sec-edgar","filing":"0000899243-21-023730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924321023730/doc4.xml","form_type":"4"}},{"id":2984118,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-12T17:51:37.000Z","date":"2020-11-09","kind":"purchase","acquired":true,"shares":332293,"price":10.3,"value":3422617.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 9, 2020, BC Perception Holdings, LP (\"BC Perception\") purchased 332,293 shares of the Issuer's Common Stock at a price of $10.30 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Christopher Gordon is a Managing Director of Bain Capital Investors, LLC (\"BCI\"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the managing directors of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":60632356,"source":{"system":"sec-edgar","filing":"0000899243-20-030857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924320030857/doc4.xml","form_type":"4"}},{"id":2998187,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-29T20:00:08.000Z","date":"2020-10-27","kind":"purchase","acquired":true,"shares":10000000,"price":10,"value":100000000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 27, 2020, BC Perception purchased 10,000,000 shares of the Issuer's Common Stock from the Issuer at a price of $10.00 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Christopher Gordon is a Managing Director of Bain Capital Investors, LLC (\"BCI\"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the managing directors of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":60300063,"source":{"system":"sec-edgar","filing":"0000899243-20-029741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924320029741/doc4.xml","form_type":"4"}},{"id":2998186,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-29T20:00:08.000Z","date":"2020-10-27","kind":"other","acquired":true,"shares":49961943,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 27, 2020, Cerevel Therapeutics Holdings, Inc. (f/k/a ARYA Sciences Acquisition Corp II, the \"Issuer\") consummated a business combination (the \"Business Combination\") pursuant to which Cassidy Merger Sub 1, Inc., a wholly-owned subsidiary of the Issuer merged with and into Cerevel Therapeutics, Inc. (\"Cerevel\"). At the effective time of the Business Combination, each share of Cerevel outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Cerevel vested equity value of $780,000,000. As a result, BC Perception Holdings, LP (\"BC Perception\") received 49,961,943 shares of the Issuer's Common Stock in consideration for the equity securities of Cerevel held by BC Perception prior to the Business Combination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 27, 2020, Cerevel Therapeutics Holdings, Inc. (f/k/a ARYA Sciences Acquisition Corp II, the \"Issuer\") consummated a business combination (the \"Business Combination\") pursuant to which Cassidy Merger Sub 1, Inc., a wholly-owned subsidiary of the Issuer merged with and into Cerevel Therapeutics, Inc. (\"Cerevel\"). At the effective time of the Business Combination, each share of Cerevel outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an implied Cerevel vested equity value of $780,000,000. As a result, BC Perception Holdings, LP (\"BC Perception\") received 49,961,943 shares of the Issuer's Common Stock in consideration for the equity securities of Cerevel held by BC Perception prior to the Business Combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Christopher Gordon is a Managing Director of Bain Capital Investors, LLC (\"BCI\"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the managing directors of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":50300063,"source":{"system":"sec-edgar","filing":"0000899243-20-029741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000089924320029741/doc4.xml","form_type":"4"}},{"id":3944208,"issuer":{"id":4312,"kind":"organization","name":"Acadia Healthcare Company, Inc."},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-07T16:18:49.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares will vest over a 3-year period in equal annual installments beginning May 3, 2019."}],"balance_after":12328,"source":{"system":"sec-edgar","filing":"0000899243-18-011637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1432313/000089924318011637/doc4.xml","form_type":"4"}},{"id":4225466,"issuer":{"id":4312,"kind":"organization","name":"Acadia Healthcare Company, Inc."},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01","published_at":"2017-08-24T17:44:59.000Z","date":"2017-08-22","kind":"sale","acquired":false,"shares":998438,"price":50.69,"value":50610822.22,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of Common Stock held directly by Bain Capital Fund VIII, LLC, Bain Capital VIII Coinvestment Fund, LLC, Bain Capital (CR), L.P., BCIP Associates III, LLC, BCIP Associates III-B, LLC, BCIP T Associates III, LLC, BCIP T Associates III-B, LLC, and BCIP Associates-G (collectively, the \"Bain Capital Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Capital Entities is directed by the Global Private Equity Board of Bain Capital Investors, LLC (\"BCI\"). Christopher Gordon is a Managing Director of BCI. By virtue of the relationships described in these footnotes, Mr. Gordon may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Entities. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-17-020976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1432313/000089924317020976/doc4.xml","form_type":"4"}},{"id":4245575,"issuer":{"id":4312,"kind":"organization","name":"Acadia Healthcare Company, Inc."},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01","published_at":"2017-08-02T16:06:48.000Z","date":"2017-07-31","kind":"sale","acquired":false,"shares":2453764,"price":51.65,"value":126736910.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of Common Stock held directly by Bain Capital Fund VIII, LLC, Bain Capital VIII Coinvestment Fund, LLC, Bain Capital (CR), L.P., BCIP Associates III, LLC, BCIP Associates III-B, LLC, BCIP T Associates III, LLC, BCIP T Associates III-B, LLC, and BCIP Associates-G (collectively, the \"Bain Capital Entities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The governance, investment strategy and decision-making process with respect to investments held by the Bain Capital Entities is directed by the Global Private Equity Board of Bain Capital Investors, LLC (\"BCI\"). Christopher Gordon is a Managing Director of BCI. By virtue of the relationships described in these footnotes, Mr. Gordon may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by the Bain Capital Entities. Mr. Gordon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":998438,"source":{"system":"sec-edgar","filing":"0000899243-17-019535","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1432313/000089924317019535/doc4.xml","form_type":"4"}},{"id":4302895,"issuer":{"id":4312,"kind":"organization","name":"Acadia Healthcare Company, Inc."},"owners":[{"id":82302,"kind":"person","name":"Gordon Christopher R","position":1,"cik":"0001432313","reported_name":"Gordon Christopher R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01","published_at":"2017-05-26T16:23:57.000Z","date":"2017-05-25","kind":"grant","acquired":true,"shares":3752,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares will vest over a 3-year period in equal annual installments beginning May 25, 2018."}],"balance_after":8203,"source":{"system":"sec-edgar","filing":"0000899243-17-014549","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1432313/000089924317014549/doc4.xml","form_type":"4"}}]}